Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EXS73565 · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| EXS73565 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| EXS73565 | DRUG | EXS73565 oral administration |
Key Inclusion Criteria: * Age ≥18 years at the time of signing the informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's trans...
EXS73565 is an investigational small molecule being developed for the treatment of relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and Waldenstrom's macroglobulinemia.
EXS73565 targets MALT1, a protein involved in B-cell signaling pathways. By inhibiting MALT1, the drug aims to disrupt survival signals in malignant B-cells, potentially leading to their death. This mechanism is being studied in patients with relapsed or refractory B-cell malignancies.
EXS73565 is being developed by Recursion Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RXRX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with relapsed or refractory B-cell malignancies.
EXS73565 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is a dose-determining study designed to evaluate the drug's safety, tolerability, and pharmacokinetics in patients with relapsed or refractory B-cell malignancies.
EXS73565 is being studied in a Phase 1 clinical trial registered as NCT06980116. This is a dose-determining study in participants with relapsed or refractory B-cell malignancies, including CLL/SLL, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, DLBCL, and Waldenstrom's macroglobulinemia. The trial is currently recruiting participants across multiple countries in Europe.
No alternative names for EXS73565 have been disclosed. The drug is identified solely by its code name EXS73565 in clinical trial registrations and company communications. It is a distinct investigational compound being developed by Recursion Pharmaceuticals for the treatment of relapsed or refractory B-cell malignancies.